Sakar Healthcare posts Rs 11 cr profit in Q2
Benchmarks Nifty22,753.20153.21FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.52 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return17.9 % Invest NowEnter search…
Benchmarks Nifty22,753.20153.21FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.52 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return17.9 % Invest NowEnter search text:
The company said the second quarter growth was supported by new oncology approvals, strong demand across geographies, a better oncology mix, operating leverage, and disciplined cost management.
Sakar Healthcare Managing Director Sanjay Shah said, "Q2 has been a quarter of meaningful progress for our oncology business, with encouraging developments across regulatory approvals, technology transfers and global market access."
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onsakar healthcareSakar Healthcare Q2 profitnew delhiSakar Healthcarequarterly resultcorporate news
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onsakar healthcareSakar Healthcare Q2 profitnew delhiSakar Healthcarequarterly resultcorporate news
The company said the second quarter growth was supported by new oncology approvals, strong demand across geographies, a better oncology mix, operating leverage, and disciplined cost management.
New Delhi: Sakar Healthcare on Friday reported a consolidated net profit of Rs 11.30 crore for the September quarter. The company had posted a net profit of Rs 4.54 crore in the year-ago period. Its revenue from operations rose 51.9 per cent to Rs 87.41 crore during the quarter from Rs 57.56 crore a year earlier, according to a regulatory filing.The company said the second quarter growth was supported by new oncology approvals, strong demand across geographies, a better oncology mix, operating leverage, and disciplined cost management.
Sakar Healthcare Managing Director Sanjay Shah said, "Q2 has been a quarter of meaningful progress for our oncology business, with encouraging developments across regulatory approvals, technology transfers and global market access."
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onsakar healthcareSakar Healthcare Q2 profitnew delhiSakar Healthcarequarterly resultcorporate news
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
...moreless(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onsakar healthcareSakar Healthcare Q2 profitnew delhiSakar Healthcarequarterly resultcorporate news
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
...morelessStories you might be interested in
Source: Economic Times — Healthcare/Biotech ↗
Figures reflect the source report and its stated period. This article is for information and is not investment advice.
